Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer

Table 1 Positivity comparison between H pylori -specific IgG and HP-NAP-specific antibodies in healthy individuals n (%)

	Total number tested	Positivity
HP-specific IgG Abs	89	47 (52.8)
HP-NAP-specific Abs (total healthy persons)	89	13 (14.6)1
HP-NAP-specific Abs (infected healthy persons)	47	13 (27.7)

¹P < 0.005 vs infected healthy persons; Abs: Antibodies.

Table 2 Demonstration of antibodies against HP-NAP in serum from H pylori-infected patients by ELISA n (%)

Patient group	Positivity for HP-NAP antibodies	Negativity for HP-NAP antibodies	Absorbance (mean ± 2SD) (cut-off value 0.78)	Range
Gastric cancer group (n = 43)	42 (97.7)	1 (2.3)	1.01 ± 0.24	0.748-1.269
Peptic ulcer group (n = 28)	26 (92.8)	2 (7.1)	0.98 ± 0.32	0.771-1.265
Chronic gastritis group (n = 28)	24 (85.7)	4 (14.3)	0.89 ± 0.14	0.711-1.122
Healthy persons (HP-IgG positive n = 47)	13 (27.7)	34 (72.3)	0.65 ± 0.18	0.451-0.948

Table 3 IL-8 level in culture supernatant of human gastric epithelial cell line SCG7901 (pg/mL)

Time (h)	IL-8 level
	10 &mgr;g/mL NAP	1 &mgr;g/mL LPS	Control
12	10.10b	8.07	3.55
36	30.14b	30.54	11.28

^bP < 0.01 vs control.